Biogen Inc (BIIB – Q1FY20) – Biogen look forward to grow from aducanumab in Alzheimer’s disease.

in , on June 22, 2020

Biogen has opened BLA and has started to submit modules, expects to complete the U.S. filing for (Alzheimer’s drug) aducanumab in Q3FY20. It also initiated re-dosing study for aducanumab and higher dose study for SPINRAZA. The company entered collaboration with Sangamo Therapeutics for gene regulation therapies for neurological disease.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY20 Results – Overview.
– Q1FY20 – Product Revenues.
– Q1FY20 – Key Developments
– Conclusion
– GAAP to Non-GAPP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

Release Information

  • Released

    June 22, 2020

  • Last Updated

    June 22, 2020